Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunogen Inc (NQ: IMGN )

29.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Immunogen Inc

< Previous 1 2 3 4 5 6 7 Next >
Earnings Scheduled For February 25, 2022
Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •... 
Via Benzinga
Earnings Outlook For Immunogen
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B
ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and... 
Via Benzinga
Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer
Sutro Biopharma could still find a place for itself in ovarian cancer treatment. 
Via Investor's Business Daily
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
10 Biggest Price Target Changes For Wednesday
Morgan Stanley boosted Zscaler, Inc. (NASDAQ: ZS) price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in pre-market trading. Citigroup boosted Applied... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of ADP, Manufacturing Data
Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains in the previous session. Investors are awaiting earnings results from G-... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Cumberland (NASDAQ:CPIX) stock... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Lannett (NYSE:LCI) shares rose 11.61... 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
Exposures Product Safety
Why ImmunoGen Stock Soared Today
The cancer-fighting specialist's new antibody treatment could be a gamechanger. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.44% to 34,628.69 while the NASDAQ fell 1.34% to 15,571.16. The S&P also fell, dropping 1.36% to 4,592.03. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
These 2 Nasdaq Biotechs Are Bucking the Market Downtrend
Wall Street is having a bad day, but shareholders in these companies are celebrating. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump
Midway through trading Tuesday, the Dow traded down 0.88% to 34,827.81 while the NASDAQ fell 0.78% to 15,659.31. The S&P also fell, dropping 0.3832% to 4,616.53. The U.... 
Via Benzinga
Topics Stocks
Exposures US Equities
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
Exposures Product Safety
ImmunoGen Shares Rally After Ovarian Cancer Trial Meets Primary Endpoint Goal
ImmunoGen Inc (NASDAQ: IMGN) shares have gained more than 30% during premarket trading in reaction to positive topline data from the SORAYA trial of mirvetuximab... 
Via Benzinga
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Cumberland (NASDAQ:CPIX) shares rose 91.81% to $4.22 during Tuesday's pre-market session. The company's market cap stands at $62.4 million. First Wave... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about! 
Via InvestorPlace
Exposures Product Safety
ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript
IMGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
Recap: Immunogen Q3 Earnings
Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, October 29, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Outlook For Immunogen
Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2021-10-29. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Scheduled For October 29, 2021
Companies Reporting Before The Bell • Sify Technologies (NASDAQ:SIFY) is expected to report quarterly earnings at $0.02 per share on revenue of $97.70 million. •... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.